Immunovant, Inc. (IMVT)
| Market Cap | 990.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -111.19M |
| Shares Out | 115.00M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,648 |
| Open | 8.70 |
| Previous Close | 8.61 |
| Day's Range | 8.55 - 8.79 |
| 52-Week Range | 6.68 - 53.75 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 18.00 (+109.1%) |
| Est. Earnings Date | Nov 9, 2021 |
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for Immunovant stock is "Strong Buy." The 12-month stock price forecast is 18.00, which is an increase of 109.06% from the latest price.
News
Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1
Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant Company Ended the Quarter With Cash of Approximately $379 Mil...
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Why Shares of Immunovant Are Down Almost 10% This Afternoon
An analyst note is extending yesterday's sell-off.
Why Shares of Immunovant Are Tanking Today
Shareholders are throwing in the towel after not getting the deal they were expecting.
Immunovant Stock Plunges After Credit Suisse Downgrade Citing Unclear Catalysts
Credit Suisse downgraded Immunovant Inc (NASDAQ:IMVT) to Underperform from Neutral and lowered the price target to $7 from $12. Analyst Tiago Fauth says that the downgrade reflects ongoing clinical and...
Immunovant Stock Plunges On $200M Equity Investment From Roivant To Support IMVT-1401 Development
Immunovant Inc (NASDAQ: IMVT) has received a $200 million strategic investment from Roivant Sciences that the Company will use to advance IMVT-1401 in multiple indications. Roivant has purchased around ...
Immunovant Receives $200 Million Strategic Investment from Roivant Sciences
NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
Biotech Losers In 2021 That Could Bounce Big In The Second Half
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...
Immunovant, Inc. (IMVT) Up 6.6% Since Last Earnings Report: Can It Continue?
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4
Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401.
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today provid...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourag...
LOS ANGELES, April 20, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "t...
APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plainti...
NEW YORK, April 19, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class acti...
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encou...
Los Angeles, California--(Newsfile Corp. - April 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...
IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lea...
New York, New York--(Newsfile Corp. - April 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions...
New York, New York--(Newsfile Corp. - April 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm
Atlanta, Georgia--(Newsfile Corp. - April 16, 2021) - Holzer & Holzer, LLC reminds investors who suffered financial losses on purchases of Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT)...
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and...
(Newsfile Corp. - April 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions...
New York, New York--(Newsfile Corp. - April 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Imm...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant...
LOS ANGELES--(BUSINESS WIRE)---- $IMVT #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. (IMVT)
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. a...
Los Angeles, California--(Newsfile Corp. - April 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Immunovant, Inc. ("Im...
IMVT Approaching Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and ...
New York, New York--(Newsfile Corp. - April 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Immunovant, Inc. ("Immunovant" or "the Co...